These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
4 files

Sebum: a window into dysregulation of lipid metabolism in Parkinson’s disease

revised on 28.06.2020, 10:56 and posted on 30.06.2020, 06:49 by Eleanor Sinclair, Drupad Trivedi, Depanjan Sarkar, Caitlin Walton-Doyle, Joy Milne, Tilo Kunath, Anouk Rijs, Rob Debie, Royston Goodacre, Monty Silverdale, Perdita Barran

A metabolomics profiling approach was conducted to identify diagnostic biomarkers of PD from sebum, a non-invasively available biofluid. In this study, we used liquid chromatography-mass spectrometry (LC-MS) to analyse 274 samples from participants (80 drug naïve PD, 138 medicated PD and 56 well matched control subjects) and detected metabolites that could predict PD phenotype. Partial least squares-discriminant analysis (PLS-DA) models based on this sebum metabolome had correct classification rates of 70.4% and 69.7% to distinguish between drug naïve PD and medicated PD from control, respectively. Variable importance in projection (VIP) scores indicate compounds with significance belonged to sphingolipid, triacylglycerol and fatty acid/ester lipid classes. Pathway enrichment analysis showed alterations in lipid metabolism and mitochondrial dysfunction viz. the carnitine shuttle, sphingolipid metabolism and arachidonic acid metabolism. This study unveiled novel diagnostic sebum-based biomarkers for PD, and provides insight towards our current understanding of the pathogenesis of PD.


Michael J. Fox - Research grant 12921

BBSRC BB/L015048/1

Parkinson UK K-1504


Email Address of Submitting Author


The University of Manchester


United Kingdom

ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of Interest